Novel antibiotics: DEINOVE signs an agreement with the Institut Pasteur (Pasteur MS Carnot Institute) to explore the potential of new targeted strains

04 2019
Les Carnot et les entreprises

DEINOVE, a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-based active ingredients for cosmetics and nutrition, has announced that it will benefit from the Institut Pasteur's provision of biological resources for the research of new antimicrobial agents from original strains. The Institut Pasteur (Pasteur MS Carnot Institute), one of the most renowned worldwide players in the area of infectious disease research, will entrust a targeted selection of strains from their bacterial collection to DEINOVE.

As Isabelle BUCKLE, Executive vice president for Research Applications and Industrial Partnerships at Institut Pasteur & Deputy Manager of Pasteur MS Carnot Institute, detailed, “Antimicrobial resistance is among the Institut Pasteur’s top three scientific priorities, and the development of industrial partnerships with French SMEs is at the heart of our economic development strategy in the coming years. In this context, the DEINOVE platform will allow us to quickly assess the potential of our strains. "